Source: Annual Congress 2010 - The role of biomarkers in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Beau-Faller, A. Degeorges, E. Rolland, M. Mounawar, M. Antoine, V. Poulot, A. Mauguen, V. Barbu, F. Coulet, J. L. Pretet, I. Bièche, H. Blons, J. C. Boyer, M. P. Buisine, F. De Fraipont, S. Lizard, P. Saulnier, S. Olschwang, D. Prunier-Mirebeau, N. Richard, C. Danel, E. Brambilla, C. Chouaid, G. Zalcman, P. Hainaut, S. Michiels, J. Cadranel (Strasbourg, Paris, Villejuif, Lyon, , Besançon, Saint-Cloud, Nîmes, Lille, Grenoble, Dijon, Marseille, Angers, Caen, France). Accuracy of EGFR and K-Ras mutation detection in non small cell lung carcinoma: Ring trial in 15 molecular French laboratories (ERMETIC project – Part 1). Eur Respir J 2010; 36: Suppl. 54, 1949

Member's Comments

No comment yet.

Related content which might interest you: Detection of lung cancer on CXR – A comparison of radiologist‘s performance Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010 Expression of D2-40 in small cell lung carcinomas (SCLC); Association with lymphatic invasion(L.I), clinical parameters and prognosis Source: Annual Congress 2010 - New mechanisms and markers in human lung cancer Year: 2010 Relevance of clinical TNM-staging in small cell lung cancer (SCLC) for survival – A retrospective case study in 633 patients Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Study of the use of Chartis® pulmonary assessment system to optimize subject selection for endobronchial lung volume reduction (ELVR) – Results and subgroup analysis Source: Annual Congress 2011 - Endoscopic lung volume reduction: hype or hope? Year: 2011 Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Inhibitor of DNA-binding (Id) – 1 and 3 proteins overexpression has impact on prognosis of lung adenocarcinoma Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Multiple kinds of cancer in one person – Lung and breast cancer – And other malignant entities Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 Identification of occupational lung cancer (OLC) or environmental lung cancer (ELC) by lung tissue optical mineralogic analysis(LTOMA) associated to standardised questionnaire (SQ) – About sixty-five cases Source: Annual Congress 2010 - Epidemiology of lung cancer Year: 2010 Prognostic factors affecting survival in cases with lung cancer [A lung cancer mapping project in Turkey (LCMPT)] Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 The results of drug resistance survey of MDR-strains on second line drugs obtains in national reference laboratory – " M.Nasta " Institute – Bucharest Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 KRAS mutations in non-small cell lung cancer (NSCLC) – Experiences by routine molecular testing in a German lung cancer centre Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Relapse after radical surgery for non-small cell lung cancer 2005-2009 – A retrospective quality management analysis Source: Annual Congress 2011 - How to improve lung cancer care Year: 2011 Non-small cell lung cancer – Advanced disease: Barriers to inclusion in clinical trials and its impact on survival Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 PCD – As serious as CF in every day lung clinic? Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Mesothelioma in England – results from the national lung cancer audit 2005-2007 Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 EGF-receptor mutation in non-small cell lung cancer – Experiences by routine molecular testing in a German lung cancer centre Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 EGFR and hTERT mRNA expression in non-small cell lung cancer patients – Diagnostic and prognostic implications Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 The prevalence of metastasis to the aortopulmonary window lymph nodes (stations 5 and 6) in patients with left lung carcinoma: A retrospective analysis of 566 patients Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013